Amgen, Inc.

Amgen's inebilizumab, an antibody-based therapy, showed efficacy in reducing generalized myasthenia gravis (gMG) severity in a Phase 3 trial (MINT). The study involved gMG patients positive for anti-AChR or anti-MuSK antibodies, with inebilizumab significantly improving MG-ADL and QMG scores compared to placebo, without new safety concerns. Inebilizumab targets CD19 on B-cells to reduce self-reactive antibody production.

AI-powered collaborations drive billion-dollar deals, accelerating antibody design, biopharmaceuticals, and next-gen biologics development.

Tulisokibart, an anti-TL1A monoclonal antibody, outperformed placebo in inducing clinical remission at week 12 in moderate to severe ulcerative colitis, according to the ARTEMIS-UC trial. The study incorporated a predictive biomarker for response, showing significant clinical remission, endoscopic improvement, and clinical response in patients on tulisokibart compared to placebo. A phase 3 program is planned to confirm these results.

Amgen presents new data on IMDELLTRA™ (tarlatamab-dlle), a DLL3-targeting BiTE® molecule, at the 2024 WCLC, highlighting its efficacy in extensive-stage small cell lung cancer (ES-SCLC) as both a monotherapy and in combination with PD-L1 inhibitors.

Amgen's TEPEZZA (teprotumumab) approved by Japan's Ministry of Health for active thyroid eye disease (TED), marking the first treatment in Japan for this condition. The approval is based on the OPTIC-J study, which showed significant improvement in proptosis with Tepezza treatment. TEPEZZA is also approved in the U.S., Brazil, and Saudi Arabia, with ongoing reviews in Europe, Canada, and Australia.

Avantor enters 10-year virtual power purchase agreement for 25GWh of renewable energy annually from 2026, supporting three new solar projects in Spain. The agreement reflects Avantor's commitment to reducing greenhouse gas emissions and lowering supply chain costs.

FDA approves IntraBio's drug Aqneursa for Niemann-Pick disease type C, Amgen reports success for eczema and myasthenia gravis treatments, AI tool TxGNN identifies old drugs for rare diseases, and rapamycin is explored for anti-aging benefits.

Inebilizumab-cdon shows efficacy in treating IgG4-related disease and generalized myasthenia gravis in phase 3 trials, reducing flare risk by 87% and improving daily activities, with no new safety signals identified.

Amgen's Phase 3 results for rocatinlimab in atopic dermatitis and Uplizna in myasthenia gravis were met with skepticism by analysts, who noted rocatinlimab's underwhelming efficacy and safety concerns, while Uplizna's potential as a second-line treatment was seen as sizable but not a threat to market leaders.